Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03853356

Evidence For Fusion In Spine With Orthoss®

This study aims to evaluate the performance and safety of the Orthoss® as a bone graft extender in lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitätsklinikum Augsburg - Neurochirurgische Klinik und Poliklinik, Augsburg, Germany

Loading trial locations.

About this study

This clinical investigation is a prospective, non-interventional, uncontrolled clinical trial, organized to generate clinical data on performance and safety of Orthoss® as a bone graft extender mixed with local bone at ratio of 1:1 and pedicle bone marrow aspirate in lumbar spondylodesis involving 1-2 levels. (Orthoss® is CE marked for this indication).

If you as a patient have a wear and tear disease of the spine, an operation serves to restore the stability of the spinal column. In order to promote a bony build-up of the lumbar spine segment (fusion), bone replacement material is used in your case as standard. The aim of this observational study is to determine fusion in order to address clinical performance of that bone replacement material.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient (male or female) must be 18 years or older
  • The patient must be a candidate diagnosed with either degenerative disc disease including 1-2 level (L4-L5 and/or L5-S1) or dysplasic spondylolisthesis (degree 1 or 2) or lumbar stenosis
  • If the patient is of child-bearing potential, the patient confirms not to be pregnant
  • The patient is able to comply with the clinical investigation-related procedures such as attending all follow-up procedures
  • The patient is able to fully understand the nature of the proposed surgery and is able to provide a signed informed consent including the use of the anonymized data for scientific publication
  • The patient will not participate in another clinical investigation during this clinical investigation

Exclusion criteria

  • General contraindications for surgical treatment are present
  • The patient has a history of malignancy, radiotherapy, or chemotherapy for malignancy within the past five years
  • The patient is currently being treated with radiation, chemotherapy, immunosuppression or steroid therapy dose equivalent of more than 5mg prednisolon
  • The patient is pregnant or nursing
  • Women of childbearing age who are not using a highly effective method of birth control
  • The patient has acute or chronic infection at the surgical site
  • The patient has a known allergy to bovine bone material
  • The patient has a medical history of alcohol or drug abuse within the last year prior to the screening examination
  • Vulnerable population
  • Patient is currently participating, or has participated in another clinical investigation within 6 months

Treatment and study plan

Orthoss

Device

Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.

Primary outcomes

  1. Fusion rate

    Time frame: 6 months

    Successful fusion should be based on the translational motion < 3mm as well as on the angular motion < 5° at 6 months.

Secondary outcomes

  1. Clinical Outcome Measure - Quality of Life: Oswestry Low Back Disability Index

    Time frame: 1-4 weeks; 3, 6, 12 and 24 months

    Improvement in Oswestry Low Back Disability Index (ODI) of 15 or more at 24 months from the pre-operative value.Zero is equated with no disability and 100 is the maximum disability possible.

  2. Clinical Outcome Measure - Leg pain

    Time frame: 1-4 weeks, 3,6,12 and 24 months

    Decrease in Visual Analog Scale for Pain (VAS) for leg by 3/10 or more at 24 months from the pre-operative value. Patients rated their leg pain intensity on a scale from 0-10, with a score of 0 representing "no pain" and a score fo 10 representing "pain as bad as it could be".

  3. Clinical Outcome Measure - Back pain

    Time frame: 1-

    Decrease in Visual Analog Scale for Pain (VAS) for back by 3/10 or more at 24 months from the pre-operative value. Patients rated their back pain intensity on a scale from 0-10, with a score of 0 representing "no pain" and a score fo 10 representing "pain as bad as it could be".

Sponsors and collaborators

Lead sponsor

Geistlich Pharma AG

Industry

Registry information

Acronym: EFFISO

Important dates

Study start
2019
Primary completion
2025
Study completion
2027
First posted
Feb 25, 2019
Registry last updated
Sep 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.